期刊
NATURE BIOMEDICAL ENGINEERING
卷 6, 期 7, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41551-022-00902-5
关键词
-
资金
- National Institutes of Health [HL123920, HL144002, HL146153, HL147357, HL149940, HL154154, HL164998]
- American Heart Association [18TPA34230092, 19EIA34660286]
Researchers have developed an inhalable and room-temperature-stable virus-like particle COVID-19 vaccine that induces systemic and mucosal immune responses in small animals. The vaccine, consisting of a recombinant SARS-CoV-2 receptor-binding domain conjugated to lung-derived exosomes, enhanced the retention of the receptor-binding domain in the respiratory airway and lungs, and cleared SARS-CoV-2 pseudovirus in mice. In hamsters, the vaccine attenuated severe pneumonia and reduced inflammatory infiltrates after a challenge with live SARS-CoV-2.
An inhalable virus-like-particle consisting of exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain is stable at room temperature and elicits systemic and mucosal immune responses in small animals. The first two mRNA vaccines against infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that were approved by regulators require a cold chain and were designed to elicit systemic immunity via intramuscular injection. Here we report the design and preclinical testing of an inhalable virus-like-particle as a COVID-19 vaccine that, after lyophilisation, is stable at room temperature for over three months. The vaccine consists of a recombinant SARS-CoV-2 receptor-binding domain (RBD) conjugated to lung-derived exosomes which, with respect to liposomes, enhance the retention of the RBD in both the mucus-lined respiratory airway and in lung parenchyma. In mice, the vaccine elicited RBD-specific IgG antibodies, mucosal IgA responses and CD4(+) and CD8(+) T cells with a Th1-like cytokine expression profile in the animals' lungs, and cleared them of SARS-CoV-2 pseudovirus after a challenge. In hamsters, two doses of the vaccine attenuated severe pneumonia and reduced inflammatory infiltrates after a challenge with live SARS-CoV-2. Inhalable and room-temperature-stable virus-like particles may become promising vaccine candidates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据